{"doi":"10.1002/adhm.202502454","title":"Advancing Targeted Drug Delivery in Glioblastoma Multiforme Through Biomimetic Nanomedicine Using 3D Tumor‐On‐a‐Chip Model","abstract":"The prognosis of glioblastoma multiforme (GBM) remains dismal, despite standard treatment regimens. A key challenge in treating GBM is the persistence of glioma stem cells (GSCs) within the perivascular niche (PVN) - a protective tumor microenvironment (TME) that is often associated with inadequate drug penetration. Current preclinical models do not capture complexity of the human TME, particularly the vasculature and niche-specific interactions that drive GBM progression. To overcome these limitations, an innovative 3D ex-vivo tumor-on-a-chip (TOC) platform is engineered to accurately replicate the structural and functional characteristics of the PVN. Using this platform, this study demonstrates that monocyte membrane-coated nanoparticles (MoNP) effectively target the abnormal tumor microvasculature, offering a promising approach to enhance drug delivery to these hard-to-reach GSCs. The results show that the therapeutic agent verteporfin, when delivered via MoNP, significantly inhibited GSC growth and invasiveness, while the free-form drug showed minimal efficacy. Comprehensive transcriptomic profiling and cytokine analysis validated the TOC model's ability to reflect authentic GSC responses and confirmed that MoNP-mediated verteporfin delivery effectively modulates key tumor-related signaling pathways. This integrated TOC-MoNP platform represents a clinically relevant tool that bridges the gap between traditional preclinical models and human disease, providing new opportunities for developing more effective GBM therapies.","journal":"Advanced Healthcare Materials","year":2025,"id":526800,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9549,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1169055,"name":"Ting‐Yun Wang","orcid":"0000-0001-6769-9408","position":1,"is_corresponding":false},{"id":899030,"name":"Shivani Mantri","orcid":null,"position":2,"is_corresponding":false},{"id":1403425,"name":"Hanan Alarnous","orcid":null,"position":3,"is_corresponding":false},{"id":410979,"name":"Shwetal Mehta","orcid":"0000-0002-5653-2490","position":4,"is_corresponding":false},{"id":1403426,"name":"Kuei‐Chun Wang","orcid":null,"position":5,"is_corresponding":false},{"id":288463,"name":"Mehdi Nikkhah","orcid":"0000-0001-5970-7666","position":6,"is_corresponding":false},{"id":1045362,"name":"Twinkle Jina Minette Manoharan","orcid":"0009-0007-4059-7963","position":0,"is_corresponding":true}],"reference_count":83,"raw_metadata":null,"created_at":"2026-07-19T02:50:34.851930Z","pmid":"40919708","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}